SCHEMBL10459237

SCHEMBL10459237

CC(C)(CN)CNc1cccc(-c2n[nH]c3ncccc23)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 14/20 0.47
CDC7 O00311 3/20 0.47
DAPK3 O43293 3/20 0.47
ROCK2 O75116 3/20 0.47
PRKD3 O94806 3/20 0.47
MAP4K4 O95819 3/20 0.47
PAK4 O96013 3/20 0.47
PRKACA P17612 3/20 0.47
CDK2 P24941 3/20 0.47
FLT3 P36888 3/20 0.47
CSNK1A1 P48729 3/20 0.47
CLK2 P49760 3/20 0.47
CDK7 P50613 3/20 0.47
CDK9 P50750 3/20 0.47
PRKX P51817 3/20 0.47
JAK3 P52333 3/20 0.47
CDK5 Q00535 3/20 0.47
MAP4K2 Q12851 3/20 0.47
STK3 Q13188 3/20 0.47
CAMK2D Q13557 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10323983 0.89 PIM1 (0.46) PIM1CDC7DAPK3ROCK2PRKD3
SCHEMBL10459265 0.81 CDK2 (0.46) PIM1CDC7DAPK3ROCK2PRKD3
SCHEMBL10459165 0.81 PIM1 (0.61) PIM1PIM3PIM2SYKIRAK4
SCHEMBL10459404 0.78 PIM1 (0.50) PIM1CDC7ROCK2PRKD3MAP4K4
SCHEMBL10459231 0.76 PIM1 (0.47) PIM1CDK9PIM3PIM2MAPK8
SCHEMBL10459247 0.76 PIM1 (0.43) PIM1CDK2CDK5PIM3PIM2
SCHEMBL10459216 0.75 PIM1 (0.44) PIM1CDC7ROCK2PRKACACDK2
SCHEMBL10457549 0.75 PIM1 (0.43) PIM1PIM3PIM2MAPK8MAPK9
SCHEMBL10459276 0.74 PIM1 (0.43) PIM1PIM3PIM2SYKMAPK8
SCHEMBL10459260 0.74 PIM1 (0.41) PIM1CDK2CDK5PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9137973-B2 Pyrazolopyridine kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-09-22 US disclosed
US-9137973-B2 Pyrazolopyridine kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-09-22 US disclosed
US-9029546-B2 Pyrazolopyridine kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-05-12 US disclosed
US-9029546-B2 Pyrazolopyridine kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-05-12 US disclosed
US-20140148434-A1 PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-29 US disclosed
US-20140148434-A1 PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-29 US disclosed
US-20120184524-A1 PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2012-07-19 US disclosed
US-20120184524-A1 PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148434-A1 PYRAZOLOPYRIDINE KINASE INHIBITORS MAP3K5, MAP3K20, MAP3K1 PIM1 220/4885CDC7 421/4885DAPK3 177/4885
US-20120184524-A1 PYRAZOLOPYRIDINE KINASE INHIBITORS MAP3K5, MAP3K20, MAP3K1 PIM1 220/4885CDC7 421/4885DAPK3 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.